Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 499

2.

Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.

Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2003 Feb;160(2):290-6.

PMID:
12562575
3.

The effects of novel antipsychotics on glucose and lipid levels.

Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC.

J Clin Psychiatry. 2002 Oct;63(10):856-65.

PMID:
12416594
4.

Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study.

Smith RC, Lindenmayer JP, Hu Q, Kelly E, Viviano TF, Cornwell J, Vaidhyanathaswamy S, Marcovina S, Davis JM.

Schizophr Res. 2010 Jul;120(1-3):204-9. doi: 10.1016/j.schres.2010.04.001. Epub 2010 May 10.

PMID:
20457512
5.

Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis.

Henderson DC, Cagliero E, Copeland PM, Borba CP, Evins E, Hayden D, Weber MT, Anderson EJ, Allison DB, Daley TB, Schoenfeld D, Goff DC.

Arch Gen Psychiatry. 2005 Jan;62(1):19-28.

PMID:
15630069
6.

Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study.

Smith RC, Lindenmayer JP, Davis JM, Kelly E, Viviano TF, Cornwell J, Hu Q, Khan A, Vaidhyanathaswamy S.

J Clin Psychiatry. 2009 Nov;70(11):1501-13. doi: 10.4088/JCP.08m04446yel. Epub 2009 Oct 6.

PMID:
19814947
7.

Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine.

Kelly DL, Conley RR, Love RC, Morrison JA, McMahon RP.

Ann Clin Psychiatry. 2008 Apr-Jun;20(2):71-8. doi: 10.1080/10401230802017050.

PMID:
18568578
8.

A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone.

Newcomer JW, Ratner RE, Eriksson JW, Emsley R, Meulien D, Miller F, Leonova-Edlund J, Leong RW, Brecher M.

J Clin Psychiatry. 2009 Apr;70(4):487-99. Epub 2009 Apr 7.

9.

Comparison of long-term (at least 24 weeks) weight gain and metabolic changes between adolescents and adults treated with olanzapine.

Kryzhanovskaya LA, Xu W, Millen BA, Acharya N, Jen KY, Osuntokun O.

J Child Adolesc Psychopharmacol. 2012 Apr;22(2):157-65. doi: 10.1089/cap.2010.0020. Epub 2012 Feb 28.

PMID:
22372514
10.

A naturalistic comparison of clozapine, risperidone, and olanzapine in the treatment of bipolar disorder.

Guille C, Sachs GS, Ghaemi SN.

J Clin Psychiatry. 2000 Sep;61(9):638-42.

PMID:
11030483
11.

Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.

Kinon BJ, Basson BR, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Feb;62(2):92-100.

PMID:
11247108
12.

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

Atmaca M, Kuloglu M, Tezcan E, Ustundag B.

J Clin Psychiatry. 2003 May;64(5):598-604.

PMID:
12755665
13.

Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled.

McKee JR, Bodfish JW, Mahorney SL, Heeth WL, Ball MP.

J Clin Psychiatry. 2005 Sep;66(9):1161-8.

PMID:
16187775
14.

Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine.

Yasui-Furukori N, Sato Y, Furukori H, Saito M, Nakagami T, Kaneko S.

J Clin Psychiatry. 2009 Jan;70(1):95-100.

PMID:
19026267
15.

Elevated levels of insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses.

Melkersson KI, Hulting AL, Brismar KE.

J Clin Psychiatry. 2000 Oct;61(10):742-9.

PMID:
11078035
16.
17.

Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder.

Hardy TA, Henry RR, Forrester TD, Kryzhanovskaya LA, Campbell GM, Marks DM, Mudaliar S.

Diabetes Obes Metab. 2011 Aug;13(8):726-35. doi: 10.1111/j.1463-1326.2011.01398.x.

PMID:
21435142
18.

Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.

Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD.

J Clin Psychiatry. 2001 Apr;62(4):231-8.

PMID:
11379836
19.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
20.

A crossover study on lipid and weight changes associated with olanzapine and risperidone.

Su KP, Wu PL, Pariante CM.

Psychopharmacology (Berl). 2005 Dec;183(3):383-6. Epub 2005 Oct 21.

PMID:
16240162

Supplemental Content

Support Center